Print

Active Biotech Interim Report January-June 2007

2007-08-09

For further information, please contact:
Sven Andréasson
President and CEO
Tel: +46 (0)46-19 20 49
Cecilia Hofvander
Manager Corporate Communications
Tel: +46 (0)46-19 11 22

Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724
SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50This report is also available at www.activebiotech.com
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio focused on autoimmune/inflammatory diseases and cancer. Its most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and ANYARA, for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds - TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the I-3D project in preclinical development is being carried out jointly with Chelsea Therapeutics.

pdfActive Biotech AB Interim Report Jan-Jun 2007



Back